These data suggest that the addition of LABAs to higher efficacy NR3C1 ligands may represent a superior means to treat steroid-resistant inflammatory conditions such as severe asthma and COPD. This evidence concerns the gene NR3C1 and chronic obstructive pulmonary disease.